SeaStar Medical Holding Corporation (ICU)
| Market Cap | 31.92M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.23M |
| Shares Out | 65.15M |
| EPS (ttm) | -1.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,021,249 |
| Open | 0.443 |
| Previous Close | 0.436 |
| Day's Range | 0.443 - 0.503 |
| 52-Week Range | 0.162 - 2.280 |
| Beta | -1.15 |
| Analysts | Strong Buy |
| Price Target | 5.00 (+920.62%) |
| Earnings Date | Apr 16, 2024 |
About ICU
SeaStar Medical Holding Corporation, a medical device company, develops a platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers inflammatory response to fend off infections and repair damaged tissue in the body. It is also developing products in various therapeutic areas, including pediatric and adult acute kidney injury on CRRT; cardiorenal syndrome in congestive heart failure; myocardial stunning in end stage renal disease; and hepatorenal syndrome. SeaStar Medical Holding Co... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for ICU stock is "Strong Buy" and the 12-month stock price forecast is $5.0.
News
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of SeaStar Medical Holding Corporation - ICU
NEW YORK , April 20, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SeaStar Medical Holding Corporation ("SeaStar" or the "Company") (NASDAQ: ICU). Such investors...
SeaStar Medical Reports 2023 Financial Results and Provides a Business Update
DENVER, April 17, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solu...
SeaStar Medical to Present at the Noble Capital Markets' Emerging Growth Virtual Healthcare Equity Conference
DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of h...
SeaStar Medical to Restate Financials, Sets Business Update Call for April 17
Restatement of non-cash items is not expected to materially impact cash position or operations DENVER, March 27, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercia...
SeaStar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients
Company plans to hold a business update conference call in April DENVER, March 12, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial stage medical device company...
SeaStar Medical-Sponsored Symposium Featuring Experts Discussing Pediatric Acute Kidney Injury and the Selective Cytopheretic Device to be Webcast Live at AKI & CRRT 2024
March 13 webcast showcasing Quelimmune ™ scientific background and clinical data for pediatric AKI due to sepsis or a septic condition will be available on seastarmedical.com
Manuscript Discussing the Benefit of SeaStar Medical's Selective Cytopheretic Device in Patients with Heart Failure and Hyperinflammation Published in European Journal of Heart Failure
Interest continues to grow in developing new strategies to reduce systemic inflammation as a means of improving outcomes in heart failure patients
FDA Grants Humanitarian Device Exemption Approval to SeaStar Medical's Selective Cytopheretic Device for Pediatric Acute Kidney Injury
SCD-PED (Pediatric) is the first FDA-approved product in the Company's Quelimmune™ product family
ICU stock price: Here's why SeaStar Medical shares have surged
SeaStar Medical Holding (NASDAQ: ICU) stock price has done well this year even as the company continued diluting its shareholders. The stock is about to hit $1, meaning that it has surged by more than...
SeaStar Medical Granted Canadian Patent with Broad Claims Covering the Selective Cytopheretic Device Technology
DENVER, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Announces Pricing of $9.0 Million Registered Direct Offering Priced At-the-Market
DENVER, Jan. 26, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (the “Company”), a medical technology company developing proprietary solutions to reduce the consequences of...
SeaStar Medical Appoints David A. Green as Chief Financial Officer
DENVER, Jan. 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Issued U.S. Patent with Broad Claims Covering Use of the Selective Cytopheretic Device for Multiple Clinical Indications
DENVER, Jan. 09, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury
DENVER, Dec. 28, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Forms Scientific Advisory Board of World-Renowned Pediatric and Adult Clinical Experts
DENVER, Dec. 13, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...
SeaStar Medical Reports Third Quarter 2023 Financial Results and Provides a Business Update
DENVER, Nov. 14, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce th...
FDA Issues Approvable Letter for SeaStar Medical's Selective Cytopheretic Device for Pediatric Patients
DENVER, Oct. 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of dysregulated immune...
SeaStar Medical's stock more than doubles in 2 days to get back above the $1 level
Shares of SeaStar Medical Holding Corp. ICU, +70.05% rocketed 45.3% on heavy volume in premarket trading Thursday, to take them back above the $1 mark for the first time in five months. Trading volume...
FDA Grants SeaStar Medical's Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome
DENVER, Oct. 18, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical to Present at the Dawson James Small Cap Growth Conference on October 12, 2023
DENVER, Oct. 05, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...
SeaStar Medical Provides Regulatory Update Regarding Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under a Humanitarian Device Exemption
Com pany to finalize labeling with FDA Approv able Letter expected within a month
FDA Grants Breakthrough Device Designation to SeaStar Medical's Selective Cytopheretic Device for Cardiorenal Syndrome
DENVER, Sept. 29, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation ...
SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
DENVER, Aug. 22, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a medical device company developing proprietary solutions to reduce th...
SeaStar Medical Reports Second Quarter 2023 Financial Results and Provides a Business Update
Management to hold a b usiness u pdate c onference c all on August 2 2 beginning at 4 :00 p.m. Eastern time
SeaStar Medical to Sponsor the Critical Care Time Podcast Series Covering Vital Medical Issues for Healthcare Professionals Who Care for Critically Ill Patients
DENVER, June 30, 2023 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a medical device company developing proprietary solutions to reduce the consequences of hyperinflammation o...